# **Resource Summary Report**

Generated by NIF on May 6, 2025

## **Ontario Cancer Biomarker Network**

RRID:SCR\_012616

Type: Tool

## **Proper Citation**

Ontario Cancer Biomarker Network (RRID:SCR\_012616)

#### Resource Information

**URL:** http://www.scienceexchange.com/facilities/ontario-cancer-biomarker-network

**Proper Citation:** Ontario Cancer Biomarker Network (RRID:SCR\_012616)

**Description:** THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 14,2024. OCBN is a not-for-profit corporation that was established in 2005 with a grant from the Ontario Institute for Cancer Research and the Ontario Ministry of Research and Innovation for the purpose of advancing biomarker research. The OCBN is designed to enable the co-ordination and amplification of the proteomic and genomic biomarker research efforts throughout the province of Ontario to better service academia and industry, whether provincially, nationally or internationally. As such, OCBN is much more than simply an academic research consortium. Residing at the core of the network is the OCBN Central Facility, located at the MaRS Incubator www.marsdd.com in the heart of the biomedical research community in Toronto, one of the most vibrant research hubs in the world. The Central Facility functions as the nexus for the network and its academic and industry partners by providing numerous support services for their clinical and basic research scientists in the conduct of their research.

**Abbreviations: OCBN** 

Resource Type: core facility, access service resource, service resource

**Funding:** 

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Ontario Cancer Biomarker Network

Resource ID: SCR 012616

Alternate IDs: SciEx\_56

**Record Creation Time:** 20220129T080311+0000

Record Last Update: 20250506T061209+0000

### Ratings and Alerts

No rating or validation information has been found for Ontario Cancer Biomarker Network.

No alerts have been found for Ontario Cancer Biomarker Network.

#### Data and Source Information

Source: SciCrunch Registry

### **Usage and Citation Metrics**

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF.

Echeverría-Garcés G, et al. (2024) Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology. Frontiers in pharmacology, 15, 1373007.

Pérez-Villa A, et al. (2023) Integrated multi-omics analysis reveals the molecular interplay between circadian clocks and cancer pathogenesis. Scientific reports, 13(1), 14198.

Varela NM, et al. (2021) A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. Frontiers in pharmacology, 12, 630658.